Effect of an Emollient Cream Containing a Milk Bioactive Peptide on Clinical Signs, Pruritus and Bacterial Colonization of Mild Atopic Dermatitis Skin Lesions in Pediatric Population (NCT07259343)
Effect of Glycomacropeptide on Clinical Manifestations of Atopic Dermatitis in Children: a Pilot Study
🩺 Plain-English Summary (8th-Grade Level)
The goal of this clinical trial is to evaluate the protective effect of glycomacropeptide on the clinical signs and symptoms of atopic dermatitis in children aged 2 to 12 years, and to determine if topical administration of glycomacropeptide is associated with a lower colonization by Staphylococcus species on the skin. The main questions that it aims to answer are: * Does glycomacropeptide reduce the signs and symptoms related to atopic dermatitis in the pediatric population? * Does glycomacropeptide modify the colonization of Staphylococcus species in atopic dermatitis lesions in the pediatric population? Researchers will compare an emollient cream containing glycomacropeptide with an emollient cream without glycomacropeptide to evaluate whether treatment with glycomacropeptide achieves a greater reduction in the clinical severity and pruritus of atopic dermatitis and a lower bacterial colonization compared with the exclusive use of emollients. Participants will: * Read and sign the informed consent * Undergo a prick test at the first visit to ensure no reaction to the treatment components * Receive the assigned treatment (glycomacropeptide cream or emollient cream), which must be applied twice daily only to atopic dermatitis lesions. * Visit the clinic once a week for 4 weeks for follow-up and SCORAD assessments, and for skin sample collection by stripping at first and last visit.
Who can join: Review the eligibility criteria below.
Location: Universidad Autónoma de Aguascalientes — Aguascalientes, Aguascalientes
Age range: 2 Years to 12 Years
🧪 Interventions in This Study
- glycomacropeptide (OTHER)
- emollient cream (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Universidad Autónoma de Aguascalientes — Aguascalientes, Aguascalientes
📞 Contact the Study Coordinator
Phone: 52 449-910-8424
Email: maria.salinas@edu.uaa.mx
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Atopic Dermatitis (AD)
- Effectiveness of Psychodermatologic Educational Modules on Atopic Dermatitis Patient Outcomes — Edmonton, Alberta
- A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis — Phoenix, Arizona
- Moisturization and Skin Hydration Study — Vancouver, British Columbia
- Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis — Fargo, North Dakota
- The Impact of Botox on Neuroimmune Interactions in Atopic Dermatitis — Pittsburgh, Pennsylvania
Explore by condition: All Atopic Dermatitis (AD) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.